Natural Products for Preventing/Treating Chemotherapy-Induced Peripheral Neuropathy
A special issue of Future Pharmacology (ISSN 2673-9879).
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 484
Special Issue Editors
Interests: molecular pharmacology; pain; nutritional immunology; nature compounds; opioid; chronic inflammatory diseases
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; anticancer drug discovery; cancer pharmacology; proteomics
Special Issues, Collections and Topics in MDPI journals
Interests: pharmacology; genetics; hematology; oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chemotherapy-induced peripheral neuropathy (CIPN) has been a serious health concern affecting the quality of life of cancer survivors. However, there are only minimally effective methods to treat or prevent CIPN despite over 20 years of research and nearly 100 clinical trials in humans. Therefore, discovering new medicines for CIPN is highly demanded. Natural products, including terpenes, alkaloids, flavonoids, and cannabinoids, have demonstrated themselves as strong candidates for developing new drugs for pain treatment with potential mechanisms including reducing the production of inflammatory mediators, promoting antioxidant signaling, and neuroprotective effects. This Special Issue aims to highlight the latest research on the discovery of novel CIPN therapy and the exploration of the mechanisms of action. We sincerely invite researchers to contribute original research (preclinical and/or clinical) or review articles focusing on the management of neuropathic pain.
Dr. Wei Lei
Dr. Xin Chen
Dr. Tuoen Liu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chemotherapy-induced peripheral neuropathy
- pain
- natural product
- neuroinflammation
- Nrf2
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
